eMedevents
  • 137227+ Medical Conferences
  • 251 Specialties
  • 10487 Organizers
  • 151845 Speakers
  • 156 Countries
  • 4558 Cities
45742+
CME Conference Registrations Sold
Home  >  Speakers  >  David J. Sourdive
David J. Sourdive

David J. Sourdive

    PhD
Co-Founder, Executive Vice President | Paris, Ile-de-France    France
Virology
Virology, Immunology And Microbiology,...More
Spoken at 4 events

Biography :

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition.

He served as Executive Vice President, Corporate Development, from 2008 to 2016. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

**********************
*** * ** ** ** **
 
For speaker's contact information - Contact us

Specialties

Virology

Interested Topics

Virology, Immunology and Microbiology, Oncology, Life Sciences, Technology Transfer, Business Development

State Licenses

This section has yet to be updated by the speaker.

Board Certifications

This section has yet to be updated by the speaker.

Professional Association

This section has yet to be updated by the speaker.

Languages

English

Conference Session Materials

The conference session material has yet to be added by the speaker.
Close

Send Message